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Abstract
Rhesus monkey rhadinovirus (RRV) is a -2-herpesvirus that is closely related to Kaposi’s sarcoma-associated herpesvirus (KSHV/
HHV-8). Lack of an efficient culture system to grow high titers of virus, and the lack of an in vivo animal model system, has hampered
the study of KSHV replication and pathogenesis. RRV is capable of replicating to high titers on fibroblasts, thus facilitating the construction
of recombinant rhadinoviruses. In addition, the ability to experimentally infect naı¨ve rhesus macaques with RRV makes it an excellent model
system to study -herpesvirus replication. Our study describes, for the first time, the construction of a GFP-expressing RRV recombinant
virus using a traditional homologous recombination strategy. We have also developed two new methods for determining viral titers of RRV
including a traditional viral plaque assay and a quantitative real-time PCR assay. We have compared the replication of wild-type RRV with
that of the RRV-GFP recombinant virus in one-step growth curves. We have also measured the sensitivity of RRV to a small panel of
antiviral drugs. The development of both the recombination strategy and the viral quantitation assays for RRV will lay the foundation for
future studies to evaluate the contribution of individual genes to viral replication both in vitro and in vivo.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
In 1994, Chang and Moore identified Kaposi’s sarcoma-
associated herpesvirus (KSHV/HHV-8) in Kaposi’s sar-
coma biopsies by representative differential analysis (Chang
et al., 1994). KSHV has since been implicated as the caus-
ative agent for Kaposi’s sarcoma (Ganem, 1998; Kedes et
al., 1996; Miller et al., 1996; Moore and Chang, 1995),
primary effusion lymphomas (Cesarman et al., 1995; Chang
et al., 1994), and multicentric Castleman’s disease (MCD)
(Gessain et al., 1996; Soulier et al., 1995). Understanding
the replication and pathogenesis of this virus has proven to
be difficult due to the lack of an efficient lytic system to
grow high titers of virus. KSHV studies involving the lytic
cycle must be carried out in latently infected B cell lines
using an artificial reactivation with phorbol esters, such as
n-butyrate or tetradecanoyl phorbol acetate (TPA) (Miller et
al., 1997; Renne et al., 1996). This scenario is unfavorable
for a number of reasons including the fact that there is a
very high background of latency, as only 25–30% of cells
reactivate, and the potential for TPA-related artifacts (Chan
et al., 1998; Renne et al., 1996). Alternatively a number of
endothelial cell based systems have been established by
several laboratories (Dezube et al., 2002; Lagunoff et al.,
2002; Sakurada et al., 2001), but an inability to serially
transmit the virus over an extended passage of time coupled
with a high background of latency in these cell lines is a
limiting factor for studying the KSHV lytic cycle. As a
result, studies of either the KSHV viral replicative cycle or
the consequences of infection on the host cell are very
difficult to interpret. Other animal model systems have been
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developed to assist in the understanding of -herpesvirus
replication. Murine herpesvirus 68 (MHV-68) reviewed in
Simas and Efstathiou (1998) and Herpesvirus saimiri (HVS)
reviewed in Jung et al. (1999) are two such model viruses
that have lytic cell-culture systems available.
At the New England Regional Primate Research Center
(NERPRC), Desrosiers et al. (1997) discovered a novel
-herpesvirus of rhesus monkeys (Macacca mulatta). The
genomes of two isolates of this new virus, called rhesus
monkey rhadinovirus (RRV) or RVMac2, were fully se-
quenced by the NERPRC and the Oregon Regional Primate
Research Center (Alexander et al., 1999; Searles et al.,
1999) to reveal that RRV is very closely related to KSHV.
The NERPRC RRV strain has been designated H29-95. In
addition, the concurrent finding of a cell line that supports
lytic replication of RRV was an attribute that made RRV an
attractive model to study KSHV. Since the sequencing of
RRV, several primate rhadinoviruses with more similarity
to KSHV have been discovered (Bosch et al., 1999; Rose et
al., 1997; Schultz et al., 2000; Strand et al., 2000). However,
due to complications with either virus isolation or identify-
ing permissive cell culture systems, these viruses may not
be tractable as model systems. Thus far, the RRV model has
been used to study the viral interleukin-6 homologue
(Kaleeba et al., 1999) and the R1 signaling protein (Dama-
nia et al., 1999, 2000). Further, the Rta/Orf50 immediate
early transactivator, the bZIP homolog, also known as R8 or
replication-associated protein (RAP), and the R8.1 glycop-
rotein have been identified and partially characterized inde-
pendently by two groups of investigators (DeWire et al.,
2002; Lin et al., 2002). We have also recently reported the
kinetics of gene expression with regard to immediate-early,
early, and late genes in RRV lytic infection (DeWire et al.,
2002).
Here we describe the construction of a RRV-GFP recom-
binant virus and the development of two new viral quanti-
tation assays for determining RRV titers. We compare the
replication kinetics of wild-type RRV and the RRV-GFP
recombinant virus by these two different techniques. One
assay is a traditional plaque assay based on rhesus fibro-
blasts (RhFs), and the other is a quantitative real-time PCR
assay. We demonstrate the usefulness of these assays by
performing one-step growth curves for RRV and a GFP-
expressing RRV recombinant virus and then test viral rep-
lication in the presence of several herpesviral-inhibitory
compounds. With the increasing emergence of RRV as a
model system for KSHV, we feel these assays will be
valuable for assessing the replicative abilities of RRV as
well as recombinant viruses derived from RRV, in reverse
genetic studies.
Results
Traditionally, recombinant herpesviruses have been con-
structed by homologous recombination (Cann, 1999; Roiz-
man and Jenkins, 1985). To determine a viral gene’s con-
tribution to replication and in vivo pathogenesis, one
common strategy is to make recombinant viruses targeting a
particular gene. To detect any replication defect in the
recombinant virus, sensitive assays to determine viral titer
in experimental samples are needed. In the work presented
here, we have created, for the first time, a recombinant RRV
that expresses the GFP gene and have assessed its replica-
tion in two different quantitative assays.
Construction of a RRV-GFP recombinant virus expressing
green fluorescent protein (GFP)
We set forth to make a recombinant RRV that expresses
GFP to use as a marker of infection in our quantitative
assays, and also as a highly valuable tool for studying RRV
pathogenesis in vivo in future studies. In order not to disrupt
any RRV genes or their promoters, the GFP gene was
introduced into a genomic location where two open reading
frames (ORFs) terminate adjacent to each other (Fig. 1). We
chose the region between ORFs 18 and 19, since the iden-
tical location has been disrupted in KSHV for the introduc-
tion of bacterial artificial chromosome sequences without
any consequence to viral replication (Zhou et al., 2002). A
GFP expression cassette driven by the cytomegalovirus im-
mediate-early promoter was introduced using a traditional
homologous recombination approach by cotransfection with
RRV virion DNA into rhesus fibroblasts. A single plaque of
GFP-expressing virus (Fig. 2) was purified four times by
using limiting dilution, and a final purification by flow
cytometry was performed. Purity and integrity of the virus
was confirmed by different methods.
To verify that the insertion of exogenous sequences oc-
curred only at the desired location, we performed Southern
hybridization analysis (Figs. 3A, B, and C). The strategy we
used to perform the Southern blots is depicted in Fig. 3A.
Virion DNA from wt RRV and the RRV-GFP recombinant
virus was isolated and restriction digested with SacI. The
DNA fragments were electrophoresed on an agarose gel and
the gel was transferred to nitrocellulose. A Southern blot
was performed using two different probes. Probe A was
complementary to a region in ORF 18 and should hybridize
to a 1876-bp fragment in wt RRV digested with SacI and to
a 3532-bp fragment in RRV-GFP virion DNA digested with
SacI. As can be seen in Fig. 3B, each of the wt RRV and
RRV-GFP recombinant viruses gave us fragments of the
expected size. Probe B was complementary to the GFP gene
and when used in a Southern blot, we expected it to hybrid-
ize to the 3532-bp fragment of the SacI-digested RRV-GFP
DNA. Since the GFP gene is not present in wt RRV, we did
not expect Probe B to hybridize to wt RRV DNA. Fig. 3C
depicts the Southern blot performed on the samples using
Probe B and shows that the GFP cassette was inserted into
the RRV-GFP recombinant virus in the correct site and as
expected, was absent in WT RRV DNA.
To further confirm our results, we also performed PCR
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amplification using primers flanking the ORF 18/19 junc-
tion (Fig. 3D). With the wt RRV virion DNA we were able
to PCR-amplify the expected fragment of 150 bp using
these primers, and with the RRV-GFP recombinant virion
DNA, we PCR-amplified the expected fragment of 1800 bp
using the same primers (Fig. 3D). We also performed DNA
sequencing of these fragments and reconfirmed the integrity
of these PCR-amplified fragments (data not shown).
Finally, to ensure that gene expression from the flanking
ORFs 18 and 19 were not interrupted by the insertion of the
GFP cassette into the RRV-GFP recombinant virus, we
performed RT-PCR analysis on cells infected with both wt
RRV and RRV-GFP recombinant viruses. Cells were in-
fected with the respective viruses and poly(A) mRNA was
isolated 72 h postinfection. RT-PCR was performed using
primer sets that amplified ORF 18 and 19 transcripts, re-
spectively. As can be seen in Fig. 3E, RT-PCR analysis of
ORF 18 and 19 gene transcription in both parental WT RRV
virus (lane 1) and recombinant RRV-GFP virus (lane 3)
demonstrated that these flanking ORFs were transcribed to
similar levels. Lanes 2 and 4 represent samples in which no
reverse transcriptase was added to the RT-PCR reaction. As
further confirmation that the RRV-GFP virus was not de-
fective, plaques produced by the RRV-GFP virus were
approximately the same size and grew with the same kinet-
ics as the wild-type RRV H26-95 parent virus (Fig. 2).
The RRV plaque assay
Traditionally, the plaque assay has been the best means
of quantifying viral loads. Plaque assays have been previ-
ously described for a number of herpesviruses (Garabedian
and Scott, 1967; Gerna and Chambers, 1976; Wentworth
and French, 1969, 1970; Yazaki et al., 1966). However, the
agarose overlay based approach for plaque assays, which is
widely used for many -herpesviruses, was not tractable to
the RRV lytic system. Here we report the development of a
plaque assay for RRV based on a methyl-cellulose contain-
ing overlay. We attempted to assess RRV replication in a
number of common cell types including 293-HEK, Vero,
human embryonic lung, RhFs, and normal human fibro-
blasts. None of these cell types except for the rhesus fibro-
blasts were capable of supporting RRV replication and
hence we designed our plaque assay using this cell line.
Confluent monolayers of RhFs in 12-well dishes were in-
fected with serially diluted RRV-H26-95 from a viral stock.
After a viral adsorption incubation, wells were overlaid with
a methyl-cellulose-containing media and then incubated at
37°C for 8 days, allowing plaques to form. A variety of
overlay medias containing low-melt agarose from 0.6 to
1.2% and methyl-cellulose from 0.3 to 1.2% were attempted
and it was found that the best media for efficient plaquing
and cellular survival was 0.75% methyl-cellulose. After 7
days of incubation, overlay media was removed and cells
were fixed and stained with crystal violet. A typical plaque
assay dish is shown in Fig. 2B (panel A) and a typical RRV
plaque is shown in Fig. 2D.
Use of RRV-GFP to determine plaquing efficiency
Next, we determined if every virus that infects cells on
the plaque assay monolayer actually forms a plaque. The
RRV system is said to be a completely lytic system, and
using this virus and the plaquing technique we could con-
firm this assumption. To answer this question, we used the
recombinant GFP-expressing virus, RRV-GFP (Figs. 1 and
Fig. 1. A schematic representation of the construction of RRV-GFP. The region of the RRV genome between ORFs 18 and 19 was targeted for the
introduction of a GFP expression cassette under the CMV promoter. This cassette was cloned into a plasmid in between the coding sequences for ORFs 16–18
and ORFs 19–21. The plasmid was then cotransfected into rhesus fibroblasts along with virion DNA, and a single GFP-expressing virus was purified.
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2), and traced the fate of GFP-expressing cells. We per-
formed the aforementioned plaque assay with the recombi-
nant virus and observed GFP expression through the micro-
scope. At 2 days postinfection, we counted the number of
GFP-positive cells in each well of the plaque assay dishes.
Following the 7 day incubation, we counted the plaque
numbers first by GFP expression and then by crystal violet
staining. We concluded that every cell that expresses GFP at
2 d.p.i. contributes to a plaque at day 8, thus confirming the
100% lytic nature of RRV in rhesus fibroblasts. Fig. 2B
shows an example of a GFP-positive plaque at 7 days
postinfection in phase contrast (panel B), GFP fluorescence
(panel C), and final crystal violet preparation (panel D).
The RRV real-time qPCR assay
Real-time PCR, first described by Heid et al. (1996), is a
highly sensitive and accurate method for quantifying copy
number of a target DNA sequence. As a result of the speed
and reliability of these types of assays, quantitative real-
time PCR assays have been previously established for a
number of herpesviruses for use in both research and clin-
Fig. 2. Photographs of typical RRV/RRV-GFP Plaques. (A) A picture of a crystal violet preparation of a 35-mm dish from an RRV plaque assay showing
the relative size of the plaques. (B) A single RRV-GFP plaque shown under phase contrast microscopy at100 magnification while still under overlay media.
(C) The same plaque as in (B) shown with GFP excitation. (D) The same plaque as in (B) and (C) in final crystal violet preparation.
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Fig. 3. Integrity and purity of the RRV-GFP recombinant. (A) Schematic representation of the Sac1 digestion of the RRV ORF 18/19 junction. Probe A was generated from
digestion of a plasmid encoding RRV ORF 18, and probe B was generated from pEGFP-N1. (B) Southern hybridization performed with probe A, detected a 3.5-kb fragment
from RRV-GFP and a 1.9-kb fragment from the parental strain. (C) An identical Southern blot as shown in (B) that has been hybridized with probe B containing the GFP
gene. The same 3.5-kb fragment is apparent, and no other bands are present, confirming that the GFP cassette has only inserted into the ORF 18/19 junction. (D)
PCR-amplification was performed using the wt RRV and RRV-GFP recombinant virus DNA with two different sets of primers in ORFs 18 and 19 that flank the insertion
site. The arrows highlight the 1800 and 150 bp PCR-amplification products obtained from RRV-GFP and wt RRV viral DNA, respectively. (E) RT-PCR analysis of ORF18
and 19 gene expression in both recombinant (RRV-GFP) and parental virus (wt RRV). Lanes 1 and 2 represent the parental wt RRV virus, and lanes 3 and 4 represent the
RRV-GFP virus. Lanes 2 and 4 represent samples in which no reverse transcriptase was added to the RT-PCR reaction.
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ical applications (Dittmer et al., 1999; Fakhari and Dittmer,
2002; Gautheret-Dejean et al., 2002; Greenlee et al., 2002;
Kimura et al., 2002; Lo et al., 2000; Pevenstein et al., 1999;
Sanchez and Storch, 2002; White and Campbell, 2000).
In our assay, the target molecule for determining copy
number in the RRV genome was the Orf50 gene. We chose
this site for amplification because the Orf50 (Rta) homolog
in other -herpesviruses has been shown to be one of the
most essential lytic genes and the only protein necessary for
reactivation from the latent state (Sun et al., 1998). For this
reason, all functional copies of the RRV genome would
have to contain a copy of the Orf50 gene. The real-time
PCR primers and the probe were designed using the ABI
Primer Express software program to ensure maximum am-
plification efficiency. An 81-base-pair amplicon was chosen
as per the software recommendations, and we chose to use
FAM as a reporter dye and TAMRA as a quencher dye in
our dual-labeled probe.
A number of real-time PCR assays previously published
report the use of uracil-N-glycosylase (UNG) as an additive
to protect against carry-over contamination, whereby previ-
ously amplified product serves as a template for synthesis.
All of our PCR reactions were carried out in a separate
facility from where reactions were assembled, and a differ-
ent designated individual removed the amplified samples
from the machine and discarded them immediately. This
careful procedure eliminated the risk of carry-over contam-
ination because amplified product was never allowed back
into the laboratory and made the use of UNG unnecessary
for our purposes. Duplicate reactions containing either wa-
ter or UNG were run and no difference was seen between
their amplification profiles confirming this assumption (data
not shown). As a further control for the accuracy of the
real-time PCR assay, a rox dye included in the master mix
was used to normalize samples for pipetting error.
The limit of detection for the RRV real-time PCR assay
was near 10–50 copies per reaction, although the most
accurate detection was in the range of 100 to 1 million
template copies per reaction. For the set of reactions run in
this article, the slope of the standard curve was 3.32 and
the r2 value was 0.992, and this was reproducible in all the
experiments. PCR amplification efficiency, k, was calcu-
lated as a measure of exponential amplification (E), where E
 [10(1/slope)]  1 and k  1  E. Thus, the amplifi-
cation efficiency is 1.995, which is close to the ideal am-
plification efficiency of k  2 (Fakhari and Dittmer, 2002).
RRV one-step growth curve
To assess the functionality of our quantitative techniques
and compare their results, we performed a one-step growth
curve, which is the canonical assay for viral growth. Equiv-
alent plaque forming units for both RRV H26-95, the wild-
type strain, and RRV-GFP were used to infect RhFs at a
multiplicity of infection of 5. At 24-h intervals after infec-
tion, cell-free supernatants were harvested and analyzed for
viral titer by both plaque assay and real-time PCR. The
results (Figs. 4A and B) show that RRV-GFP has nearly
identical growth kinetics as wild-type RRV by both assays.
The eclipse or lag phase for RRV seems to last at least 24 h
but not more than 48 h. The single cycle of RRV replication
is around 120 to 144 h, as no significantly greater amount of
PFU/ml could be recovered after this time. Since we used
equivalent plaque forming units for both RRV and RRV-
GFP to infect RhFs, Fig. 4B shows a slight difference
between the growth curves of RRV-GFP and wild-type
virus in the real-time PCR data due to a larger amount of
free unpackaged viral DNA in the RRV-GFP virus stock
compared to the RRV.
Because the real-time PCR assay is a genome-counting
assay, we are able to count viral DNA replication inside
cells prior to viral egress. This is an advantage over the
plaque assay, which counts functional viral particles that
have exited the cell. Fig. 4C shows the intracellular viral
DNA concentration during the growth curves for the two
viruses. This type of analysis could prove to be very useful
when studying recombinant viruses with DNA replication
defects in future experiments. The RRV-GFP intracellular
viral genome curve is slightly above that of wild-type RRV
at early time points postinfection.
Sensitivity of RRV to replication inhibitors
To further show the utility of our assays for quantitation
of viral titers, the recombinant RRV-GFP virus was tested
for replication in the presence of a panel of compounds
(Figs. 5A and B). The recombinant virus was used so that
any results obtained by plaque assay and real-time PCR
concerning the relative effect of the compounds could be
correlated with the intensity of GFP expression as seen
under the microscope during the course of the infection. The
effect of two thymidine kinase (TK) directed antiviral com-
pounds, acyclovir (ACV) and ganciclovir (GCV), as well as
the herpesviral DNA polymerase inhibitor phosphonoacetic
acid (PAA), were tested at various concentrations to see if
each could effectively inhibit RRV replication up to 120 h
postinfection. Also included was cyclohexamide, a general
protein synthesis inhibitor, as a control.
It was concluded by the use of both quantitative assays
that ACV was ineffective at reducing RRV replication at all
concentrations tested. However, Kedes and Ganem (1997)
have previously shown that there is a very slight inhibition
of KSHV viral replication by acyclovir at high concentra-
tions of the drug. GCV reduced RRV titer by 1 log when
used at 100 M, and by 2 logs when used at 500 M. GCV
at 1 mM completely abolished RRV replication, as did PAA
at all concentrations as well as the positive control CHX at
0.5 g/ml. The pattern of viral replication inhibition is
consistent across the two assays, while the actual number of
genomes versus plaque forming units differs, just as in the
one-step growth curve. Although approximately 10 million
RRV genomes per milliliter present in the samples we
127S.M. DeWire et al. / Virology 312 (2003) 122–134
report have no viral replication, it should be noted that this
is the same copy number as was counted at 24 h postinfec-
tion during the one-step growth curve. Combined with the
absence of plaques for these samples, we interpret this to
mean that 107 is the approximate number of copies of the
RRV genome that remains associated with the cells and the
well itself after removal of the inoculum. Thus, these data
points represent the complete inhibition of viral replication.
Comparing viral genomes to plaque forming units
By applying these two analyses to the same set of ex-
periment samples, we can also compare the number of viral
genomes per plaque forming unit. Table 1 shows the typical
result for the ratio of genome copies per plaque at 48, 96,
and 144 h postinfection, which ranges from around 1000 to
10,000. This ratio is slightly higher for the recombinant
GFP-expressing virus and could possibly be due to the fact
that when GFP is expressed at high levels it can become
toxic to cells. This presents a possible scenario whereby
cells undergoing viral replication begin to lyse because of
the high expression levels of GFP, rather than viral egress,
releasing large amounts of free viral DNA into the media
without production of virus. Also listed in Table 1 are the
ratios of PFU per genome copies.
Discussion
In this article, we present two new viral quantitation
assays for rhesus monkey rhadinovirus, a useful animal
model system to study KSHV and  herpesvirus replication.
We have compared the functionality of these assays to
assess the replication kinetics of RRV and a recombinant
RRV-GFP virus. We have thoroughly documented the pu-
rity and integrity of the RRV-GFP recombinant virus. We
have also demonstrated that we have not disrupted tran-
scription from the open reading frames flanking the site of
insertion of the GFP cassette when creating the RRV-GFP
recombinant virus. We have shown by two different quan-
titative assays that the wt RRV and RRV-GFP viruses
display comparable replication kinetics. Further, we have
subjected the virus to replication inhibitors in an attempt to
utilize these assays to determine sensitivity of RRV to
antiviral compounds.
According to one-step growth curves performed at an
m.o.i. of 5, the amount of time it takes to complete a single
replication cycle for RRV is approximately 120 to 144 h.
The maximum titer achieved is approaching 1 million
plaque forming units per milliliter for both the wild-type
and the recombinant viruses. However, the number of viral
genomes per milliliter of culture supernatant is around 10
billion. This observation could occur for a number of rea-
sons, including the lysis of cells still undergoing viral DNA
replication releasing unpackaged viral DNA prematurely.
One way to circumvent this discrepancy in quantitation is to
treat cell-free supernatants with DNAse to degrade free viral
DNA. While this would rule out any difference due to free
viral DNA, it would not take into account packaged repli-
Fig. 4. RRV one-step growth curves. (A) Equivalent numbers of rhesus
fibroblast cells were infected with either WT RRV H26-95 (gray dia-
monds) or RRV-GFP (black squares) at an m.o.i. of 5 and cell-free
supernatants were harvested at indicated points postinfection and quanti-
tated by plaque assay. (B) The same samples as in (A) were quantitated
using the real-time PCR assay for RRV. (C) Intracellular virus concentra-
tion at indicated times after infection was quantitated by real-time PCR.
Media were removed and cells were collected by trypsinization. Cells were
lysed and DNA was extracted as described in Materials and methods.
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cation-incompetent DNA. Because in these set of experi-
ments we were only interested in observing the overall
pattern of RRV replication, this step to rid samples of free
viral DNA was omitted.
It has been previously reported that acyclovir is not an
effective antiviral compound for KSHV by a majority of
investigators (Neyts and De Clercq, 1997, and Kedes and
Ganem, 1997, no. 2451). However, it moderately affects
KSHV replication when used at very high concentrations
(Medveczky et al., 1997), and one group reports ACV
inhibits glycoprotein K8.1 expression, albeit not as well
as PAA (Zoeteweij et al., 1999). In agreement with these
data, our findings here report that RRV is unaffected by
acyclovir at concentrations up to 1 mM. In contrast,
studies in MHV-68 (Neyts and De Clercq, 1998) and
EBV (Littler and Arrand, 1988; Moore et al., 2001) have
shown that acyclovir is fairly effective at inhibiting rep-
lication, suggesting this insensitivity to acyclovir by
RRV and KSHV is not a shared property of the TK gene
of -herpesviruses in general.
Ganciclovir has been shown to be highly effective in
inhibiting KSHV replication at low concentrations (Can-
non et al., 1999; Dittmer et al., 1999; Kedes and Ganem,
1997; Neyts and De Clercq, 1997). However, one con-
flicting report suggests that the TK gene of KSHV is
incapable of phosphorylating ganciclovir (Gustafson et
al., 2000). With regard to ganciclovir, RRV is not sig-
nificantly inhibited at 10 M concentration, but suffers
successive 1 log reductions at 100 and 500 M, respec-
tively, and replication is completely abolished at a 1 mM
concentration of ganciclovir. While the concentrations
tested are much higher for RRV due to the completely
lytic nature of our system, the general pattern is consis-
tent with what has been shown for KSHV reactivation
from BCBL-1 cells (Kedes and Ganem, 1997). Differing
reports exist for the efficacy of ganciclovir on EBV,
while some show it is very effective at killing EBV
TK-expressing cells (Littler and Arrand, 1988; Moore et
al., 2001; Rogers et al., 1996); others report that the EBV
TK gene by itself cannot phosphorylate ganciclovir
(Gustafson et al., 1998). MHV-68 showed a similar sen-
sitivity to ganciclovir (Neyts and De Clercq, 1998), sug-
gesting that this compound is an effective choice for
inhibiting replication in all -herpesviruses (Neyts and
De Clercq, 1998).
PAA and foscarnet are two herpesviral DNA polymerase
inhibitors with the same mechanism of action. PAA was
inhibitory at all concentrations tested for RRV. This finding
is not surprising considering data from other herpesviruses,
which shows that the DNA polymerase gene for these vi-
ruses is highly conserved. PAA and PFA have been shown
to be highly effective inhibitors of KSHV reactivation in a
number of reports (Kedes and Ganem, 1997; Lin and Ric-
ciardi, 2000; Low et al., 1998; Medveczky et al., 1997;
Zoeteweij et al., 1999).
While in all cases mentioned above, both quantitative
assays were able to accurately measure the effectiveness of
antiviral compounds, one aspect of the real-time PCR assay
is its sensitivity to various PCR inhibitors. While most
known PCR inhibitors are derived from in vivo fluid or
tissue samples, the existing possibility that compounds used
in vitro could inhibit a PCR reaction was best illustrated to
us while performing the replication inhibition study. Poly-
brene, a polycationic lipid previously reported to increase
the infectivity of a number of viruses (Andreadis and Pals-
son, 1997; Damico and Bates, 2000) including KSHV (La-
gunoff et al., 2002), was included at four concentrations to
test its effect on RRV infectivity. Unexpectedly, it was
found that the samples containing polybrene at all concen-
trations failed to amplify during real-time PCR, despite the
cleaning of the samples using DNA-binding columns. The
Ct values reported for these samples were even lower than
the no-template control reactions, and the effect was dose-
dependent, which perhaps suggests that polybrene is a very
strong inhibitor of some aspect of the PCR reaction. This
could represent a failure to amplify target DNA, or an
inhibition of fluorescent emission, among a number of pos-
sibilities. As a result, this finding precludes the use of the
real-time PCR assay in any studies involving polybrene as a
replication enhancer, until better purification methods are
implemented.
Application of these assays to in vitro and in vivo
studies will undoubtedly assist future studies in RRV.
Deciding which assay to use will need to be dictated by
the specific experiments being performed. For example, a
recombinant RRV that is deleted for a gene necessary for
the structure of the virion will not likely show any major
DNA replication defect, and as such its replication kinet-
ics will appear identical to wild-type RRV when mea-
sured by the real-time PCR assay. However, because this
virus would not be able to form infectious particles, the
plaque assay would be the best choice to highlight the
replication defect. In contrast, the real-time PCR assay
also has specific advantages when applying a forward
genetic approach. In the case where an isolated mutant
virus exhibits a slight replication defect when measured
by the plaque assay, the real-time PCR technique would
help to determine if this defect was occurring before or
after the stage of viral DNA replication.
In summary, we have outlined the protocols for two
new viral titration assays for the quantitation of RRV,
which serves as an animal model system to study the
KSHV viral lifecycle and pathogenesis. These method-
ologies lay the foundation for future studies involving
RRV, and the study of -herpesvirus pathogenesis, in
general. We have also demonstrated for the first time that
we can construct a RRV-GFP recombinant virus using a
traditional homologous recombination strategy. This vi-
rus will prove useful in studies of RRV in its natural host,
the rhesus monkey.
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Materials and methods
Cell culture
Rhesus macaque skin fibroblasts were immortalized as
previously described (DeWire, et al., 2002). Cells were
maintained at 37°C and 5% CO2 in Dulbecco’s modified
Eagle’s medium-H (DMEM-H) with Gluta-max supple-
mented with 10% fetal bovine serum.
Virus and infections
RRV isolate H26-95 (Alexander et al., 1999) was used to
infect rhesus fibroblasts at a multiplicity of infection (m.o.i.)
of approximately 1 by standard protocols (Cann, 1999).
Ganciclovir, acyclovir, cyclohexamide (Sigma C7698), and
phosphonoacetic acid (Sigma P6909) were used at concen-
trations described in the figure legends. All compounds
were added as a mixture in fresh media after 1 h of viral
Fig. 5. Sensitivity of RRV to replication inhibitors. RRV-GFP was used at an m.o.i. of 5 to infect equal numbers of rhesus fibroblast cells for 120 h in the
presence of various inhibitors of herpesviral replication at the concentrations shown: acyclovir (ACV), ganciclovir (GCV), phosphonoacetic acid (PAA), and
as a control cyclohexamide (CHX). Viral titers were determined by plaque assay (as in A) or real-time PCR (as in B).
130 S.M. DeWire et al. / Virology 312 (2003) 122–134
infection. At various time points after infection cell-free
supernatants were harvested by centrifugation at 2000 rpm
for 5 min. For intracellular viral assays, any cellular mate-
rial pelleted from the above centrifugation was combined
with infected cells harvested by trypsinization in 500 l
PBS.
Recombinant RRV-GFP virus
A 3051-bp region of RRV H26-95 spanning nucleotides
24788 to 27839 was PCR amplified with primers 5-CG-
CCGCCTCGAGATGGCGGCTGTTCAGGGCCCT-3 and
5-CGCCGCCTGCAGCTACACTACGCTGTTATTGA-3.
This product was subsequently cloned into pSP72 (Pro-
mega) at Xho1 and Pst1 restriction sites to create pSP72-
LFR. A 3862-bp region of RRV H26-95 spanning nucleo-
tides 27847 to 31709 was PCR amplified with primers
5-CGCCGCGGATCCTCACACTACCGACGTGG-
CGACC-3 and 5-CGCCGCGATATCTTAATTGGCTG-
CATTGCTTT-3. This product was subsequently cloned
into pSP72-LFR at BamH1 and EcoRV restriction sites to
create pSP72-LFR-RFR. The multiple cloning site from
pEGFP-N1 (Clontech) was deleted by performing a BamH1
and BglII double digest, and then re-ligating the resulting
vector to form pEGFP-N1-MCS. The EGFP expression
cassette driven by the CMV IE promoter with the SV40
polyadenylation signal was PCR amplified from pEGFP-





The resulting PCR product was ligated into pSP72-LFR-
RFR to form pSP72-LFR-GFP-RFR. This plasmid was then
cotransfected with RRV-H26-95-purified viral DNA by
electroporation into RhFs at 250 V and 500 F. A single
GFP-positive virus was isolated and purified by limiting
dilution four times and by flow cytometry once.
Integrity of recombinant RRV genome
PCR primers corresponding to the ends of ORF18 and
ORF19 were used in a PCR reaction with either RRV-
H26-95 or RRV-GFP as a template. Primers were 5-GA-
TTTCGGCGTGGGATTTTGCGTCCGC-3 and 5-CG-
AGATAATGAAAAGCCAATTCGGAGT-3. Expected
product sizes were 150 bp for RRV-H26-95 and 1800
bp for RRV-GFP. The 1800 and 150 bp PCR products
from the recombinant and wt viruses were subsequently
sequenced to confirm the presence of the CMV-EGFP-pA
cassette.
Southern hybridization
Virus was harvested from cell-free media from virus-
infected cells by centrifugation at 15,000 rpm for 3 h. Virus
pellet was resuspended in PBS and treated with proteinase
K for 2 h at 56°C. Viral DNA was extracted by phenol-
chloroform method and subsequently digested with Sac1.
Digestions were electrophoresed through 1% low-melt aga-
rose (NuSieve) 1 TBE and transferred to a nylon mem-
brane (Hybond N) by capillary action. Following UV
cross-linking, membranes were prehybridized in QuikHyb
solution at 65°C for 15 min. Probes were generated from
RRV-ORF18 and GFP by random prime method using 32P
(Roche). Probes were denatured at 95°C for 3 min and
added to prehybe solution. Hybridization was carried out for
16 h at 65°C. Probe solution was removed and membranes
were washed twice for 15 min with 2 SSC 0.1% SDS at
room temperature and once for 30 min at 60°C with 0.1
SSC 0.1% SDS. Membranes were exposed and read on a
PhosphorImager Scanner (Molecular Dynamics).
RT-PCR of ORFs 18 and 19
Total RNA was extracted from RhF’s infected with ei-
ther RRV-H26-95 or RRV-GFP for 3 days using the RNA-
Stat 60 protocol as previously described (DeWire et al.,
2002). The poly A fraction was subsequently isolated using
the OligoTex system (Qiagen) according to the manufactur-
er’s protocol. Poly A RNA was then DNase1 treated by the
RQ1 protocol (Promega), and RT-PCR was performed with
the Superscript One-Step RT-PCR system (Invitrogen) as
per manufacturer’s protocol using equivalent micrograms of
starting poly A RNA. Primers were designed by W. Vahr-
son (Bioinformatics Consulting & Software Development).
Primers used for ORF 18 were 5-GAACCAAAAGCT-
CACGTTCAG-3 and 5-GATGGGTGCGAGAGGATG-
3. Primers used for ORF 19 were 5-CGCGTTCGTTGT-
CACAATAG-3 and 5-AGCCATTGGTTTTGGTTCAT-
3. Expected product sizes were 67 and 66 base pairs,
respectively.
Table 1
Comparison of viral genomes to plaque forming units





48 5.83  103 3.4  107 5.9  103 0.00016
96 4.33  105 3.2  109 7.4  103 0.00014
144 6.0  105 5.6  109 9.4  103 0.00011
RRV-GFP
48 1.50  104 1.9  108 1.3  104 0.00008
96 3.58  105 3.7  109 1.0  104 0.00009
144 4.0  105 5.7  109 1.4  104 0.00007
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Quantitative real-time PCR
For each sample, 10 g of salmon sperm carrier DNA
was added to 200 l of clarified supernatant from infected
cells and was processed through the QiaAmp DNA Blood
Mini Kit (Qiagen) as per the manufacturer’s protocol. As a
set of internal standards, the plasmid pcDNA3-RRVOrf50
(DeWire et al., 2002) was serially diluted to known con-
centrations in the range of 101 to 107 plasmid molecules per
microliter with the total concentration of DNA in each
adjusted to 50 g/ml with salmon sperm DNA. PCR reac-
tions were prepared using the Quantitect probe-PCR kit
(Qiagen) in 20 l volumes. Primers for amplification of an
81-bp amplicon internal to the Orf50 sequence were 5-
GTGGAAAGCGGTGTCACAGA-3 and 5-TGCGGCG-
GCCAAAAT-3 and the probe was 5 FAM-TTCACCAC-
CAGGCACAGACGCC-TAMRA-3. Reactions were run
in 384-well format in an ABI Prism 7900HT with the
following conditions: 95°C for 15 min, followed by 95°C
for 15 s, 60°C for 1 min repeated for 40 cycles. Cts were
determined as the first cycle where fluorescence was 10
times background. PCR amplification efficiency, k, was
calculated as a measure of exponential amplification (E),
where E  [10(1/slope)]  1 and k  1  E. The slope
was calculated to be 3.32. The amplification efficiency
was calculated to be 1.995, which is close to the ideal
amplification efficiency of k  2 (Fakhari and Dittmer,
2002).
Plaque assays
Monolayers of RhFs in 12-well plates were achieved by
plating 2  105 cells per well 2 days before starting the
assay. Dilutions of virus-infected cell supernatants were
made in DMEM-H supplemented with 2% bovine calf se-
rum (BCS). Each sample dilution was performed in tripli-
cate. Two hundred microliters of each dilution was placed in
each well of 12-well dishes and incubated at 37°C for 1 h
with redistribution of inoculum every 15 min. Inoculum was
aspirated and an overlay media was added to each well
consisting of (per well): 1 ml 2DMEM, 1 ml 1.5% meth-
yl-cellulose (Sigma M0512), and 40 l BCS (2%). Plaque
assays were then incubated 7 days at 37°C and 5% CO2.
Overlay media was then aspirated and staining solution
(0.8% crystal violet (Sigma C3886), 50% ethanol) was
added to each well and incubated 10 min. Plaques were
counted under 10 magnification.
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